Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Phoenix Canada Oil Company Limited (V:PCO)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 204 - 407 Downey Road
SASKATOON SK S7N 4L8
Tel: N/A
Website: https://www.zyus.com
IR: See website
Key People
Charlotte Moore Hepburn
Chairman of the Board
Brent Zettl
President, Chief Executive Officer
Michael D. Kindy
Chief Financial Officer
Business Overview
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
Financial Overview
For the nine months ended 30 September 2023, ZYUS Life Sciences Corp revenues increased from C$0K to C$254K. Net loss increased from C$350K to C$18.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Listing expense increase from C$0K to C$2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.07 to -C$0.29.
Employees: 2 as of Dec 31, 2005
Reporting Currency: Canadian Dollars
Enterprise value: $65.32M as of Sep 30, 2023
Annual revenue (TTM): $0.25M as of Sep 30, 2023
EBITDA (TTM): -$9.83M as of Sep 30, 2023
Net annual income (TTM): -$18.12M as of Sep 30, 2023
Free cash flow (TTM): -$15.25M as of Sep 30, 2023
Net Debt Last Fiscal Year: $1.75M as of Sep 30, 2023
Shares outstanding: 70,847,396 as of Jan 2, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization